BLUE BIRD CORP. overview

Wilkes County Schools (WCS) has marked the historic milestone of becoming the first school district in Georgia to serve all of its 25 daily bus routes exclusively with zero- and ultra-low-emission school buses. WCS’ new fleet of electric and propane-powered buses eliminates regular diesel bus routes, significantly improving air quality for students and the surrounding community, while also significantly reducing operating costs. This press release features multimedia. View the full release...

bluebird bio, Inc. (Nasdaq: BLUE) today announced new and updated data from LYFGENIA™ (lovotobegligene autotemcel, or lovo-cel) gene therapy for patients with sickle cell disease who have a history of vaso-occlusive events (VOEs). The data will be presented at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition in an oral presentation on Sunday, December 8 at 9:30 a.m. Pacific Time and a poster presentation on Sunday, December 8 at 6 p.m. Pacific Time. As of July 2024,...

bluebird bio, Inc. (Nasdaq: BLUE) today announced updated data from patients with beta-thalassemia who require regular blood transfusions treated with betibeglogene autotemcel (beti-cel, approved commercially as ZYNTEGLO™) in clinical studies. The data was presented today at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition. “Updated follow-up data of up to 10 years showed that patients treated with beti-cel in clinical trials experienced durable transfusion...

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it will proceed with a 1-for-20 reverse stock split (“Reverse Stock Split”) of the Company’s common stock following approval by both its Board of Directors and BLUE stockholders at its reconvened annual meeting held on December 4, 2024. As previously announced, the primary goal of the Reverse Stock Split is to increase the per share market price of the Company’s common stock to regain...

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio”) today announced it has reached an agreement with the Center for Medicare and Medicaid Innovation to offer an outcomes-based agreement for LYFGENIA gene therapy under the Cell and Gene Therapy (CGT) Access Model. LYFGENIA is a one-time gene therapy approved for the treatment of patients 12 years of age and older with sickle cell disease and a history of vaso-occlusive events (VOEs). “Ensuring timely, equitable access to gene therapy for...

Blue Bird Corporation (Nasdaq: BLBD), the leader in electric and low-emission school buses, lauds the U.S. expansion of Micro Bird’s manufacturing operations to build small and midsize buses in New York State. Micro Bird, a 50/50 joint venture of Blue Bird Corporation and Girardin, has confirmed the purchase of the Nova Bus facility in Plattsburgh, NY, and plans to begin production in mid-2025. The investment will enable Micro Bird to double its production capacity to better meet the sustained...

Blue Bird Corporation (“Blue Bird”) (Nasdaq: BLBD), the leader in electric and low-emission school buses, announced today its fiscal 2024 fourth quarter and full year results. Highlights (in millions except Unit Sales and EPS data) Three Months Ended September 28, 2024 B/(W) Prior Year Twelve Months Ended September 28, 2024 B/(W) Prior Year Unit Sales 2,466 350 9,000 486 GAAP Measures: Revenue $ 350.2 $ 47.2 $ 1,347.2 $ 214.4 Net Income $ 24.7 $ 6.0 $ 105.5 $ 81.7 Diluted EPS $ 0.73 $ 0.15 $...

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported third quarter results and business highlights for the quarter ended September 30, 2024, including recent commercial and operational progress. “Patient starts more than doubled from our second to third quarter update, providing clear evidence that our commercial launches continued to accelerate,” said Andrew Obenshain, chief executive officer. “This momentum, coupled with steps we took in the third...